These DCs are particularly effective in presenting tumor antigens through MHC class I (cross-presentation) and MHC class II molecules, thus eliciting strong CD8+ and CD4+ antigen-specific T cell responses [13,14]. This evidence concerns the gene CD8A and neoplasm.